AnPac Bio Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting $1 Bid Price Compliance Rule On or Before Nov. 23, 2022 Philadelphia, PA, November 4, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”)...
AnPac Bio Announces Plan to Implement ADS Ratio Change Philadelphia PA, October 18, 2022 – AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on...
AnPac Bio Announces Board and Management Changes Philadelphia PA, October 3, 2022 – AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer...
AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million Philadelphia, PA, September 26, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused...
AnPac Bio Appeals NASDAQ Delisting Notice; Hearing Granted and Scheduled for October 20, 2022 Philadelphia, PA, September 19, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United...
AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal Philadelphia, PA, September 12, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United...
AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer Philadelphia, PA, August 5, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China...
AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees Philadelphia, PA, July 18, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac...
AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market Philadelphia, PA, June 10, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States...
PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the first...
AnPac Bio Reports Fiscal Year 2021 Annual Financial Results Philadelphia, PA, May 16, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States,...
AnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capital Market Philadelphia, PA, May 11, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in...
Nasdaq Hearing Panel Grants AnPac Bio’s Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Capital Market Philadelphia, PA, May 6, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology...
AnPac Bio and New Investor Sign Equity Investment Totaling $15 Million Philadelphia, PA, April 11, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China...
AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member Philadelphia, PA, April 8, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company”...
AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late April Philadelphia, PA, April 4, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a...
AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing Philadelphia, PA, March 25, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the...
AnPac Bio-Medical Sciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement Philadelphia, PA, March 11, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United...
AnPac Bio’s Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic Alternatives Philadelphia, PA, March 2, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a...
AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA Philadelphia, PA, February 3, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United...
Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume Philadelphia, PA, January 25, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company...
AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022 Philadelphia, PA, January 4, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and...
Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal PHILADELPHIA, December 10, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with...
AnPac Bio Commences Proposed Public Offering of American Depositary Shares Philadelphia, PA, November 9, 2021 – AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on early cancer...
AnPac Bio Study Shows Strong Correlation between CDA Score and Risk of Cancer and Diseases Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed Cases Philadelphia, PA, October 4, 2021 – AnPac Bio-Medical Science Co., Ltd. (Nasdaq:ANPC, “AnPac...
AnPac Bio 2021 First Half Revenue Up 128.5% with Non-GAAP Loss Reduced by 18.3% PHILADELPHIA, October 1, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in...
AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities Deficiency PHILADELPHIA, September 30, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the...
AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% Philadelphia, Pennsylvania, September 3, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the...
AnPac Bio’s USA Laboratory Receives Accreditation from the College of American Pathologists Philadelphia, Pennsylvania, August 30, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States...
AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device PHILADELPHIA, Aug. 23, 2021 – via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company”...
AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO Philadelphia, Pennsylvania, August 17, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...
AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation to Explore Innovative Healthcare and Medical Solutions Philadelphia, Pennsylvania, August 5, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations...
AnPac Bio Announces Appointment of New Independent Director Independent Director has Strong Track Record at US Fortune 500 Companies Philadelphia, Pennsylvania, July 23, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...
FOR IMMEDIATE RELEASE AnPac Bio Enters into Contract with Cancer Treatment Company JV Partner Philadelphia, Pennsylvania, July 21, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China...
FOR IMMEDIATE RELEASE AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Over the Same Period 2020 and Q2 Paid Cancer Tests Increased Approximately 270% Over Q1 Philadelphia, Pennsylvania, July 20, 2021 – AnPac...
FOR IMMEDIATE RELEASE AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds Philadelphia, Pennsylvania, June 18, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...
AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed Philadelphia, Pennsylvania, May 27, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ:...
AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database San Jose, CA, May 24, 2021 – AnPac Bio-Medical Science Co., Ltd. (ANPC)...
AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020 FOR IMMEDIATE RELEASE San Jose, CA., April 30, 2021—AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and...
AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss) SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ:...
AnPac Bio to Report Fiscal Year 2020 Financial Results on Friday, April 30, 2021 Earnings Call Scheduled for 8:30 am ET on April 30, 2021 SAN JOSE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac...
FOR IMMEDIATE RELEASE AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 San Jose, CA, April 16, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or...
AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved Performance San Jose, CA, March 9, 2021 – AnPac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in...
AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement San Jose, CA, March 5, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused...
China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility) San Jose, CA, February 8, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a...
FOR IMMEDIATE RELEASE AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection | Continues to Innovate and Build Strong IP Portfolio San Jose, CA, February 1, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,”...
AnPac Bio Makes Significant Progress in Detecting Pre-cancer Diseases andRecorded Over 20 Types of Pre-cancer Diseases San Jose, CA, December 14, 2020 – AnPac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations...
Anpac Bio Announces Change of Auditor San Jose, CA, December 4, 2020 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer...
FOR IMMEDIATE RELEASE AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020 San Jose, CA, November 25, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a...
Anpac Bio Announces Appointment of New Independent Director San Jose, CA, November 16, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today...
FOR IMMEDIATE RELEASE AnPac Bio US Completes COVID-19 Antibody Test Verification and Approved to Begin Commercial Testing San Jose, CA, November 10, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company...
FOR IMMEDIATE RELEASE AnPac Bio’s Investee Company in China Received COVID-19 Nucleic Acid Test Certification and Began Volume Tests and Collaborations with AnPac Bio San Jose, CA, November 2, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company”...
Anpac Bio Completes Over 200,000 Biophysics Based Cancer Detection Tests, With Data Covering Close to 60 Types of Cancer San Jose, CA, October 26, 2020 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology...
FOR IMMEDIATE RELEASE AnPac Bio to Receive Up To USD $8 Million Dollar Grants and Award for R&D, Product Commercialization, and Milestone Achievements San Jose, CA, October 7, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or...
FOR IMMEDIATE RELEASE AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million San Jose, CA, October 1, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company...
FOR IMMEDIATE RELEASE AnPac Bio Receives Major Immunology Testing Contract San Jose, CA, September 15, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...
AnPac Bio Reports First Six Months of 2020 Financial Results SAN JOSE, Calif., September 10, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and...
FOR IMMEDIATE RELEASE AnPac Bio Announces Positive Results from a Multi-Year Lung Cancer Prognosis and Recurrence Clinical Study San Jose, CA, September 4, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...
AnPac Bio to Report its First Six Months 2020 Financial Results on Thursday, September 10, 2020 Earnings Call Scheduled for 8:00 am ET on September 10, 2020 San Jose, CA, August 28, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac...
FOR IMMEDIATE RELEASE AnPac Bio Philadelphia Lab Gains U.S. CLIA Lab Certification San Jose, CA, August 24, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and...
FOR IMMEDIATE RELEASE AnPac Bio Opens US Philadelphia Lab Operations San Jose, CA, August 11, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...
FOR IMMEDIATE RELEASE AnPac Bio Validating Approved COVID-19 Antibody Test San Jose, CA, August 7, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...
FOR IMMEDIATE RELEASE AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness San Jose, CA, August 4, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with...
AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests San Jose, CA, July 29, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States...
FOR IMMEDIATE RELEASE AnPac Bio Completed 1st Half Year with Increased ASP and Revenue San Jose, CA, July 13, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in...
FOR IMMEDIATE RELEASE AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening San Jose, CA, June 26, 2020 – AnPac Bio-Medical Science...
FOR IMMEDIATE RELEASE AnPac Bio Launches New Immunology Test Product Line San Jose, CA, June 22, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
FOR IMMEDIATE RELEASE AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening San Jose, CA, June 19, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in...
San Jose, CA, June 2, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced...
AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent Granted This Year in the United States San Jose, CA, May 26, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...
AnPac Bio Reports Record Revenue and Number of Cancer Risk Assessment Tests in 2019 Continued annual revenue growth Number of commercial CDA (cancer differentiation analysis)-based tests increased 26.0% year-on-year Continued to gain customers and increase the acceptance of our...
FOR IMMEDIATE RELEASE San Jose, CA., May 18, 2020—AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today...
FOR IMMEDIATE RELEASE AnPac Bio Granted New Patent in Novel Medical Device for Disease Detection in the United States San Jose, CA, May 11, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a...
AnPac Bio Receives Accreditation for United States Laboratory from College of American Pathologists SAN JOSE, Calif., March 27, 2020 -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company with operations in China and...
AnPac Bio Granted Important Novel Micro Medical Device Patent in the United States SAN JOSE, Calif., March 24, 2020 -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ: ANPC), a biotechnology company with operations in China...
FOR IMMEDIATE RELEASE AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project San Jose, CA, February 27, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in...
San Jose, CA, February 6, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that...
FOR IMMEDIATE RELEASE AnPac Bio Announces Pricing of Initial Public Offering San Jose, CA, January 30, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...
ANPAC BIO APPOINTS NOBEL PRIZE WINNER DR. MICHAEL LEVITT AS CHIEF CONSULTANT TO LEAD ANPAC’S PIONEERING EFFORTS IN CANCER SCREENING San Jose, CA – December 11, 2019 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio” or the “Company”) announced today...
Investigations on Non-Small Cell Lung Cancer Screening
AnPac Bio Gains U.S. CLIA Lab Certification SAN JOSE, California, September 26, 2019 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio”), a biotechnology company focusing on early cancer screening and detection, announced that the company's United States subsidiary, has received a certificate of registration under...
SACRAMENTO, Calif., Oct. 23, 2018 -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio), announced today that Northwestern University's Dr. Lee P. Shulman, MD, FACMG, FACOG, has joined Anpac Bio's Technical Advisory Board (TAB). It was due to...
Fellowships Fund University of California Entrepreneurship SACRAMENTO, Calif.--(BUSINESS WIRE)--Anpac Bio-Medical Science Company, and the University of California, Davis Mike and Renee Child Institute for Innovation and Entrepreneurship (UCDMRCIIE) selected five accomplished, University of California (UC) scientists to be the 2018 “Anpac Bio-Medical...
SACRAMENTO, Calif., May 21, 2018 -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, confirmed the company's 2018 revenue vaulted nearly 300% over Anpac Bio's 2017 revenue of the same period, immediately following news reports that Anpac...
Anpac Bio Receives Exceptional Reimbursement Validation Revenue in Insurance Sector Surges SACRAMENTO, CA | April 23, 2018 - Anpac Bio-Science Co., Ltd. ("Anpac Bio" hereafter), an international life science company with operations in both Asia and the US, announced today, that...
Sacramento, CA – Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced today that Anpac Bio has won the highly prestigious, international, “2018 BIG Innovation Award”. Recognizing the entire corporation for executing significant...
Super Model-Turned-SuperMogul Kathy Ireland Interviews Anpac Bio CEO For 'WorldwideBusiness' SACRAMENTO, Calif., April 20, 2018 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, was interviewed this week by "Super Model-turned-Super Mogul"...
SACRAMENTO, CA | April 16, 2018 –International life sciences and cancer screening technology corporation Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio”), recently achieved a significant milestone of receiving over seventy patents issued in twenty major countries throughout the world. Anpac Bio’s...
SACRAMENTO, Calif., Feb. 7, 2018 /PRNewswire/ -- Anpac Bio-Medical Science Company (Anpac Bio), and its internationally-acclaimed medical research partners, are celebrating "National Cancer Prevention Day" (#NationalCancerPreventionDay – February 7, 2018) by confirming a new, global milestone: Anpac Bio's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy...
SACRAMENTO, Calif., Dec. 27, 2017 -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week surpassing a new, international record. Anpac Bio's breakthrough, proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy technology identified the earliest cancer and pre-cancerous disease...
SACRAMENTO, Calif., July 17, 2017 —The Global Precision Medicine Industry Awards leadership named international life sciences corporation Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio"), the 2017, "Most Promising Cancer Screening Company" award winner; in recognition of Anpac Bio's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy cancer screening...
SACRAMENTO, Calif., March 28, 2017 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 40,000 cases worldwide of...
Seven Nobel Prize Laureates and over 20 internationally acclaimed researchers and scientists, are presenting at the third annual, "World Nobel Prize Laureate Summit" in Chengdu, China, September 2-3, 2016. The 2016 WNPLS' will feature three programs of scientific exploration: 1)...
SACRAMENTO, Calif., July 8, 2016 -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, will deliver the Keynote Address to award-winning life and technical science students, faculty, administration, corporate partners, officials, and general public,...
Anpac Fellowships Underwrite University of California Students to Attend Scientific Innovation Academies SACRAMENTO, Calif., Jan. 7, 2016 -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, has pledged $50,000 to the University of California,...
SACRAMENTO, Calif., Sept. 16, 2015 -- Anpac Bio-Medical Science Company Chief Executive Officer Dr. Chris Yu and Anpac scientists will be presenting "breakthrough," Breast Cancer screening and early detection research results at the upcoming "Breast Cancer Symposium" in San Francisco,...